MXPA04002395A - Composiciones farmaceuticas y su uso, para lograr de manera confiable niveles de testosterona en suero, aceptables en la terapia de reemplazo de testosterona. - Google Patents

Composiciones farmaceuticas y su uso, para lograr de manera confiable niveles de testosterona en suero, aceptables en la terapia de reemplazo de testosterona.

Info

Publication number
MXPA04002395A
MXPA04002395A MXPA04002395A MXPA04002395A MXPA04002395A MX PA04002395 A MXPA04002395 A MX PA04002395A MX PA04002395 A MXPA04002395 A MX PA04002395A MX PA04002395 A MXPA04002395 A MX PA04002395A MX PA04002395 A MXPA04002395 A MX PA04002395A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
testosterone
methods
testosterone levels
serum testosterone
Prior art date
Application number
MXPA04002395A
Other languages
English (en)
Inventor
Fricke Sabine
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04002395(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of MXPA04002395A publication Critical patent/MXPA04002395A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Abstract

La presente invencion se refiere a composiciones farmaceuticas, formuladas para administracion inyectable, que comprenden un ester de testosterona, en particular undecanoato de testosterona, en un vehiculo que comprende aceite de risino y un co-solvente. Despues de la inyeccion de las composiciones, de acuerdo con un esquema de administracion particular, se logran niveles confiables de testosterona en el suero en el rango fisiologico normal por un largo periodo de tiempo. Esto permite el uso de las composiciones en terapia de reemplazo de hormona y anticoncepcion del macho sin monitoreo concomitante de niveles de testosterona en el suero por un medico.
MXPA04002395A 2003-03-14 2004-03-12 Composiciones farmaceuticas y su uso, para lograr de manera confiable niveles de testosterona en suero, aceptables en la terapia de reemplazo de testosterona. MXPA04002395A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200300399 2003-03-14

Publications (1)

Publication Number Publication Date
MXPA04002395A true MXPA04002395A (es) 2004-09-20

Family

ID=32748728

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002395A MXPA04002395A (es) 2003-03-14 2004-03-12 Composiciones farmaceuticas y su uso, para lograr de manera confiable niveles de testosterona en suero, aceptables en la terapia de reemplazo de testosterona.

Country Status (40)

Country Link
US (2) US7718640B2 (es)
EP (2) EP1743646A3 (es)
JP (1) JP4680891B2 (es)
KR (2) KR100882378B1 (es)
CN (2) CN101884639A (es)
AR (1) AR043603A1 (es)
AT (1) ATE336251T1 (es)
AU (1) AU2004218893B2 (es)
BR (2) BRPI0400214A8 (es)
CA (1) CA2518910C (es)
CL (1) CL2004000527A1 (es)
CO (1) CO5700724A2 (es)
CR (1) CR7999A (es)
CY (1) CY1105794T1 (es)
DE (1) DE602004001893T2 (es)
DK (1) DK1457208T3 (es)
EA (1) EA011568B1 (es)
EC (1) ECSP056095A (es)
ES (1) ES2271772T3 (es)
HK (1) HK1069325A1 (es)
HR (1) HRP20050781B1 (es)
IL (1) IL170473A (es)
IS (1) IS2565B (es)
JO (1) JO2505B1 (es)
ME (2) ME00149B (es)
MX (1) MXPA04002395A (es)
NO (1) NO335179B1 (es)
NZ (1) NZ542321A (es)
PE (1) PE20041065A1 (es)
PL (1) PL1457208T3 (es)
PT (1) PT1457208E (es)
RS (1) RS51537B (es)
RU (2) RU2354381C2 (es)
SA (1) SA04250040B1 (es)
SI (1) SI1457208T1 (es)
TW (1) TWI345976B (es)
UA (1) UA82510C2 (es)
UY (1) UY28231A1 (es)
WO (1) WO2004080383A2 (es)
ZA (2) ZA200508313B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
WO2006113505A2 (en) * 2005-04-15 2006-10-26 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
CA2752805A1 (en) 2009-02-18 2010-08-26 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
JP6457383B2 (ja) 2012-04-06 2019-01-23 アンタレス・ファーマ・インコーポレーテッド テストステロン組成物の針支援式ジェット注入投与
TWI614035B (zh) * 2012-05-09 2018-02-11 西方健康科學大學 前體脂質體睪固酮調配物
WO2014093818A2 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
ES2763633T3 (es) 2013-02-11 2020-05-29 Antares Pharma Inc Dispositivo de inyección por chorro asistido por aguja que tiene fuerza de disparo reducida
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
US10369340B2 (en) 2013-08-12 2019-08-06 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
EP3131532A1 (de) 2014-04-16 2017-02-22 Veyx-Pharma GmbH Veterinärpharmazeutische zusammensetzung und deren verwendung
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CN105056115A (zh) * 2015-08-05 2015-11-18 成都市飞龙水处理技术研究所 一种治疗化脓性睾丸炎的内服药物及其制备方法
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
JP2022517724A (ja) * 2018-12-14 2022-03-10 アセラス バイオファーマ インコーポレーテッド テストステロンの活性エステル誘導体、組成物、およびそれらの使用
WO2021252761A2 (en) * 2020-06-11 2021-12-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4181721A (en) 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
US4242863A (en) * 1978-03-16 1981-01-06 Caterpillar Tractor Co. Dual phase fuel vaporizing combustor
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
WO1999027906A1 (en) * 1997-12-03 1999-06-10 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated castor oil
ID27260A (id) 1998-06-19 2001-03-22 Akzo Nobel Nv Turunan testosteron
AU4513099A (en) 1998-06-19 2000-01-10 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
AU768537B2 (en) 1999-04-01 2003-12-18 Merck Sharp & Dohme B.V. Formulation comprising testosteron undecanoate and castor oil
ES2253423T3 (es) * 2000-08-23 2006-06-01 Akzo Nobel N.V. Formulacion de un ester de testosterona para uso humano.

Also Published As

Publication number Publication date
WO2004080383A2 (en) 2004-09-23
CN1761469A (zh) 2006-04-19
DE602004001893T2 (de) 2007-03-15
RS20050702A (en) 2007-06-04
WO2004080383B1 (en) 2005-05-06
RU2354381C2 (ru) 2009-05-10
NO335179B1 (no) 2014-10-13
CA2518910C (en) 2009-09-08
US8338395B2 (en) 2012-12-25
PT1457208E (pt) 2007-01-31
PL1457208T3 (pl) 2007-01-31
BR122017008910A8 (pt) 2023-05-09
ECSP056095A (es) 2006-03-01
CN1761469B (zh) 2019-05-17
AU2004218893A1 (en) 2004-09-23
KR100882378B1 (ko) 2009-02-05
US7718640B2 (en) 2010-05-18
DE602004001893D1 (de) 2006-09-28
PE20041065A1 (es) 2005-02-24
IS2565B (is) 2009-12-15
CN101884639A (zh) 2010-11-17
DK1457208T3 (da) 2006-12-11
TWI345976B (en) 2011-08-01
EP1743646A3 (en) 2007-03-28
ME00149B (me) 2010-06-10
BRPI0400214A8 (pt) 2023-05-09
AU2004218893B2 (en) 2008-10-09
MEP14508A (en) 2010-06-10
WO2004080383A3 (en) 2005-03-31
SA04250040B1 (ar) 2008-01-07
AR043603A1 (es) 2005-08-03
BR122017008910A2 (es) 2005-02-09
ATE336251T1 (de) 2006-09-15
NO20054711L (no) 2005-12-13
EP1457208B9 (en) 2006-10-25
CL2004000527A1 (es) 2005-02-18
NO20054711D0 (no) 2005-10-13
CR7999A (es) 2006-05-29
US20090156564A1 (en) 2009-06-18
KR20080096717A (ko) 2008-10-31
BRPI0400214A (pt) 2005-02-09
CO5700724A2 (es) 2006-11-30
EA200501819A1 (ru) 2006-06-30
NZ542321A (en) 2008-05-30
EP1457208A1 (en) 2004-09-15
RS51537B (en) 2011-06-30
IS8069A (is) 2005-10-12
ES2271772T3 (es) 2007-04-16
SI1457208T1 (sl) 2007-02-28
ZA200700046B (en) 2008-04-30
EA011568B1 (ru) 2009-04-28
TW200511997A (en) 2005-04-01
HRP20050781B1 (hr) 2015-04-10
HK1069325A1 (en) 2005-05-20
HRP20050781A2 (en) 2005-10-31
KR20050109561A (ko) 2005-11-21
ZA200508313B (en) 2007-04-25
JO2505B1 (en) 2009-10-05
UA82510C2 (uk) 2008-04-25
EP1457208B1 (en) 2006-08-16
RU2005131724A (ru) 2006-05-10
CY1105794T1 (el) 2011-02-02
JP2006520377A (ja) 2006-09-07
UY28231A1 (es) 2004-11-08
EP1743646A2 (en) 2007-01-17
JP4680891B2 (ja) 2011-05-11
IL170473A (en) 2010-05-31
CA2518910A1 (en) 2004-09-23
RU2007118196A (ru) 2008-11-27
US20050032762A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
TW200511997A (en) Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
NZ514574A (en) Novel method of treatment
MY167123A (en) Conveniently implantable sustained release drug compositions
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1232757A4 (en) MEDICINE FOR DISEASES ASSOCIATED WITH LOSS OF BONE SUBSTANCE
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
HRP20130892T1 (hr) Farmaceutske formulacije i njihove upotrebe u lijeäśenju ženske seksualne disfunkcije
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
TW200518760A (en) Triamcinolone acetonide and anecortave acetate formulations for injection
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DE602004016963D1 (en) Therapeutisches system mit amoxicillin und clavulansäure
TNSN06072A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
CR6627A (es) Nuevo medicamento contraceptivo y su modo de preparacion
JP2003522795A5 (es)
RS100904A (en) Self-administered contraceptive injection of oily solution
MD1568F1 (en) Method of treatment of the burn disease in the burn shock period
WO2001007013A3 (en) Thioamide moiety-containing polymer drug conjugates
WO2002072016A3 (en) Method of preventing adhesions with ifn-¿y?
TW200515912A (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration
HC Change of company name or juridical status